(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 181.2MM | +11% |
Gross Profit | 133.6MM | - |
Cost Of Revenue | 47.7MM | +20% |
Operating Income | 33.2MM | +87% |
Operating Expenses | 100.4MM | - |
Net Income | 24.9MM | - |
R&D | 19.5MM | -7% |
G&A | 65.8MM | -3% |
Amortization | 14.3MM | - |
Interest Expense | 3.4MM | -2% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Pacira (PCRX) receives the FDA's RMAT designation for its gene-therapy product candidate, PCRX-201, which is currently being developed in an early-stage study to treat osteoarthritis of the knee.
-- PCRX-201 is the first gene therapy product candidate to receive RMAT designation for osteoarthritis -- -- Designation supported by encouraging preliminary data from 72-patient Phase 1 study -- -- 52-Week Data Accepted for Presentation at OARSI 2024 and 104-week data to be submitted for presentation later this year -- TAMPA, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative heal
Pacira BioSciences Inc (NASDAQ:PCRX), a pharmaceutical company specializing in non-opioid pain management and regenerative health solutions, has experienced a notable insider transaction.
TAMPA, Fla., March 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays 26th Annual Global Healthcare Conference at 1:35 PM ET on Wednesday, March 13, 2024 in Miami. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event. About Pacira Pacira BioScien
In this piece, we will take a look at the 11 best small cap pharma stocks to invest in. If you want to skip our overview of the global pharmaceutical and healthcare industry, which is one the most unique sectors in the world, then you can check out 5 Best Small Cap Pharma Stocks to […]
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2023 Earnings Call Transcript February 29, 2024 Pacira BioSciences, Inc. reports earnings inline with expectations. Reported EPS is $0.89 EPS, expectations were $0.89. Pacira BioSciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good […]
Pacira BioSciences ( NASDAQ:PCRX ) Full Year 2023 Results Key Financial Results Revenue: US$675.0m (up 1.2% from FY...
Pacira (PCRX) reports fourth-quarter 2023 results, wherein earnings match and revenues beat estimates, driven by strong Exparel sales.
Q4 2023 Pacira Biosciences Inc Earnings Call
Company Surpasses 14 Million Patient Mark with EXPAREL and Announces FDA Approvals